<DOC>
	<DOCNO>NCT00127049</DOCNO>
	<brief_summary>This prospective multicenter phase II trial gemcitabine , cisplatin , ifosfamide ( GIP ) patient relapse non-seminomatous germ-cell tumor ( NSGCT ) predict favorable prognosis .</brief_summary>
	<brief_title>Trial Gemcitabine , Cisplatin , Ifosfamide Patients With Relapsed Non-Seminomatous Germ-Cell Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Patients older 16 year Histologicallyproven disseminate ( non stage I ) NSGCT , diagnosis NSGCT base elevate serum human chorionic gonadotropin ( HCG ) and/or alpha fetoprotein ( AFP ) Relapsed disease classify good prognosis accord Memorial SloanKettering Cancer Center ( MSKCC ) classification criterion : Testicular primary site Prior treatment limit one program ( 6 few cycle cisplatin ) Either complete response partial response normal serum AFP HCG Relapse document rise AFP and/or HCG biopsy No previous carcinoma , except basalcell carcinoma skin Adequate renal function : measure calculated creatinine clearance &gt; 60 ml/min Absolute granulocyte count &gt; = 1,500/mm3 , platelet &gt; = 100,000 mm3 , bilirubin &lt; 1.5 fold upper normal value Signed informed consent . Patients infected human immunodeficiency virus ( HIV ) Patients fit inclusion criterion</criteria>
	<gender>Male</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Patients relapse non-seminomatous germ-cell tumor ( NSGCT )</keyword>
</DOC>